Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24229492 | 0.89 | HRH3 (0.44) | HRH3CYP2D6HRH1GRIN1GRIN2B | |
| SCHEMBL24229758 | 0.89 | HRH3 (0.47) | HRH3CYP2D6HRH1 | |
| SCHEMBL24229708 | 0.88 | HRH3 (0.43) | HRH3CYP2D6HRH1 | |
| SCHEMBL29052790 | 0.78 | HRH3 (0.47) | HRH3CYP2D6HRH1 | |
| SCHEMBL24229632 | 0.77 | HDAC6 (0.37) | — | |
| SCHEMBL29052789 | 0.75 | HRH3 (0.48) | HRH3CYP2D6HRH1 | |
| SCHEMBL24229711 | 0.75 | TDP1 (0.34) | CYP2D6HRH1 | |
| SCHEMBL24229760 | 0.75 | — | — | |
| SCHEMBL24229494 | 0.74 | HRH3 (0.54) | HRH3CYP2D6HRH1 | |
| SCHEMBL24239299 | 0.73 | HDAC6 (0.33) | TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| CN-116601150-A | Fused bicyclic RAF inhibitors and methods of use thereof | 爵士制药爱尔兰有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022023447-A2 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033398-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, RAF1, NRAS | HRH3 3556/4885CYP2D6 2672/4885HRH1 2821/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | HRH3 3556/4885CYP2D6 2672/4885HRH1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.